Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC.
Kidney Cancer
ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
COVID-19 Adversely Affecting Patients With Genitourinary Cancers
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Palliative Care Use in Advanced Renal Cell Carcinoma Linked to Socioeconomic Groups
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
Bone-Targeted Therapies and Incidence of Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
Effect of Hypertension History on Outcomes in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis sought to determine the effect of hypertension on overall survival, response, and progression-free survival in patients with mRCC.
NLR Rise May Predict Mortality, Treatment Failure Risks in mRCC
A rise in neutrophil-to-lymphocyte ratio of 3 or more after 2 months of therapy is associated with an increased risk for death in less than 1 year and treatment failure in less than 6 months, according to investigators.
HIF-2α Inhibitor/Cabozantinib Doublet Active in Previously Treated Advanced ccRCC
Choueiri et al tested the efficacy of the investigational hypoxia-inducible factor 2α (HIF-2α) inhibitor in combination with cabozantinib.
Real-World Data: Cabozantinib Used More Commonly Than Other TKIs After Checkpoint Inhibition in mRCC
Investigators of this retrospective observational cohort study evaluated outcomes with cabozantinib or other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (RCC) following immune checkpoint inhibition.
Nivolumab/Cabozantinib Prolongs OS in Advanced RCC With Sarcomatoid Features
CheckMate 9ER investigators assessed the efficacy of combination nivolumab and cabozantinib in the front-line sarcomatoid renal cell carcinoma (RCC) setting in an extended analysis.
-
Loading...
-
Loading...
Next post in ASCO GU 2021
